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The endogenous metabolite itaconate has recently emerged as a regulator of 
macrophage function but the precise mechanism of action remains poorly 
understood1-3. We report that itaconate is required for the activation of the 
antiinflammatory transcription factor nuclear factor-erythroid 2 p45-related 
factor 2 (Nrf2) by LPS. We find that itaconate directly modifies proteins via 
alkylation of cysteine residues. Itaconate alkylates cysteines 151, 257, 288, 273 
and 297 on Kelch-Like ECH-Associated Protein 1 (Keap1) enabling Nrf2 to 
increase expression of down-stream genes with anti-oxidant and anti-
inflammatory capacity. The activation of Nrf2 is required for the anti-
inflammatory action of itaconate. We describe the use of a new cell-permeable 
itaconate derivative, 4octyl itaconate (OI), which is protective against LPS-
induced lethality in vivo and decreases cytokine production. We show that type 
I interferons (IFN) boost immunoresponsive gene 1 (Irg1) expression and 
itaconate production. Furthermore, we find that itaconate production limits the 
type I IFN response indicating a negative feedback loop involving IFNs and 
itaconate. Our findings demonstrate that itaconate is a critical anti-inflammatory 
metabolite acting via Nrf2 to limit inflammation and modulate type I IFNs.   
  
Macrophages have a key role in innate immunity. They respond rapidly to pathogens 
and subsequently promote an anti-inflammatory phenotype to limit damage and 
promote tissue repair. The factors driving these changes are incompletely understood. 
Itaconate, a metabolite synthesized by the enzyme encoded by Irg11, is elevated in 
LPS-activated macrophages2 and has been suggested to limit inflammation by 
inhibiting succinate dehydrogenase (SDH), a critical proinflammatory regulator4, 
however, the details remain unclear.   
Itaconate was the most abundant metabolite in LPS-treated human 
macrophages (Fig. 1a) and reached 5 mM in murine bone marrow-derived 
macrophages (BMDMs) following LPS stimulation (Fig. 1b, c). Itaconate can disrupt 
SDH activity, but is less potent than the classic SDH inhibitor malonate (Extended Data 
Fig. 1), suggesting that it may exert its anti-inflammatory effects via additional 
mechanisms.   
Itaconate contains an electrophilic α,β -unsaturated carboxylic acid that could 
potentially alkylate protein cysteine residues by a Michael addition to form a 
2,3dicarboxypropyl adduct. An attractive candidate protein that undergoes cysteine 
alkylation is Keap1, a central player in the anti-oxidant response (Fig. 1d). Keap1 
normally associates with and promotes the degradation of Nrf2, however alkylation of 
critical Keap1 cysteines allows newly synthesized Nrf2 to accumulate, migrate to the 
nucleus and activate a transcriptional antioxidant and anti-inflammatory programme5. 
We therefore examined Keap1/Nrf2 as a target of itaconate.  
The cell-permeable itaconate derivative, dimethyl itaconate (DMI)3 boosted 
levels of Nrf2 protein, expression of downstream target genes, including 
hemeoxygenase (Hmox)1, and glutathione (GSH) (Extended Data Fig. 2a-d). 
However, the lack of a negative charge on the conjugated ester group in DMI increases 
its reactivity towards Michael addition, making it a far superior Nrf2 activator than 
itaconate akin to the potent Nrf2 activator dimethylfumarate (DMF)6. DMI is rapidly 
degraded within cells without releasing itaconate7, hence is unlikely to mimic 
  { PAGE   \* MERGEFORMAT }  
endogenous itaconate. Even so, these data indicate that Nrf2 activation is 
antiinflammatory (Extended Data Fig. 2e, f)8.  
To overcome the limitations of DMI, we synthesised 4-octyl itaconate (OI), a 
cell-permeable itaconate derivative (Extended Data Fig. 3a). Itaconate and OI had 
similar thiol reactivity that was far lower than that of DMI (Extended Data Fig. 3b, c, g), 
making it a suitable cell-permeable itaconate surrogate. Furthermore, OI was 
hydrolysed to itaconate by esterases in C2C12 cells (Extended Data Fig. 3d) and LPS-
activated macrophages (Extended Data Fig. 3e). OI boosted Nrf2 levels (Fig 1e, 
compare lane 5 to lane 1) and enhanced LPS-induced Nrf2 stabilisation (Fig. 1e, 
compare lane 6 to lane 2), increasing expression of down-stream target genes9, 
including the anti-inflammatory protein Hmox110 (Fig. 1f, g). We used a quantitative 
NAD(P)H:quinone oxidoreductase-1 (NQO1) inducer bioassay11,12, to assess potency 
of Nrf2 activation by the CD value (Concentration which Doubles the specific enzyme 
activity) for NQO1, the prototypical Nrf2 target gene. OI (CD = 2 µM), was more potent 
than the clinically used Nrf2 activator DMF (CD = 6.5 µM) (Fig. 1h, Extended Data Fig. 
3g). OI stimulated GSH (a key anti-oxidant) synthesis (Extended Data Fig. 3g- i). OI 
also boosted canonical activation of Nrf2 by the pro-oxidant hydrogen peroxide (H2O2) 
(Extended Data Fig. 3j, k). Importantly, 4-octyl 2-methylsuccinate (OMS) and octyl 
succinate (OS), related octyl esters, which are not Michael acceptors, had no effect on 
Nrf2 activity confirming the requirement for the itaconate moiety (Extended Data Fig. 
3l). Dimethyl malonate (DMM), a potent SDH inhibitor4, did not activate Nrf2 (Extended 
Data Fig. 3m), confirming that Nrf2 activation by OI is independent of SDH inhibition.   
Itaconate is generated by Irg1 in the mitochondrial matrix and must cross the 
mitochondrial inner membrane (MIM) to act on Nrf2 in the cytosol. Itaconate is 
structurally similar to malate, which is transported across the MIM by the dicarboxylate 
(DIC), citrate (CTP) and oxoglutarate (OGC) carriers. All three carriers transported 
itaconate, whereas other tested carriers could not (Fig. 2a and Extended Data Fig. 4) 
suggesting that LPS-induced itaconate is generated in the mitochondrial matrix and is 
then exported to the cytosol to activate Nrf2.    
Our hypothesis is that itaconate activates Nrf2 by alkylation of Keap1 cysteine 
residue(s)13-15 akin to the modification of cysteines by fumarate (Extended Data Fig. 
5a). Cysteine 151 (Cys151) is a principal sensor on Keap1 for sulforaphane (SFN)16 
and DMF17. OI stabilized Nrf2-V5 in COS1 cells co-expressing wild-type Keap1 but not 
a Cys151S mutant, similarly to SFN (Fig. 2b, compare lanes 16 and 17 to lanes 18 and 
19). To analyse Keap1 alkylation directly, we overexpressed FLAG-tagged Keap1 in 
HEK293T cells and treated with OI. Tandem mass spectrometry (MS) of 
immunoprecipitated Keap1 revealed that for the Keap1 peptide (144-152), which 
contains Cys 151, OI treatment increased its mass by 242.15 Da, consistent with 
alkylation by OI (Fig. 2c). OI also modified other known Keap1 regulatory cysteine 
residues (Cys257, Cys288 and Cys273) (Extended Data Fig.5b-d, Extended Data 
Table 1a). Furthermore, itaconate-cysteine adducts, derived in part from glucose and 
glutamine (Fig. 2d and Extended Data Fig. 6), were detected in LPS-treated 
macrophages. These data suggest that itaconate activates Nrf2 by alkylating Keap1 
cysteines. We further explored cysteine alkylation induced by itaconate using an 
untargeted MS approach in macrophages treated with OI, or with LPS which elevates 
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itaconate levels. We identified a number of proteins containing alkylated cysteine 
residues (Extended Data Table 1b, c). Notably Ldha, which has a critical role in the 
regulation of glycolysis, was alkylated in OI- and LPS-treated macrophages (Fig. 2e 
and Extended Data Fig. 5e, f). This modification, here defined as 
2,3dicarboxypropylation, generates a stable thioether. As there are no known 
pathways of removal of such PTMs modified proteins are likely degraded, suggesting 
this modification will have profound effects on macrophage function.  
 We next assessed whether itaconate activation of Nrf2 could be 
antiinflammatory. OI, used at concentrations which did not affect cellular viability, 
decreased LPS-induced IL-1β  mRNA, pro-IL-1β  and HIF-1α protein levels, 
extracellular acidification rate (ECAR) and IL-10 yet had no effect on NFκB activity or  
TNF-α (Fig. 3a, b and Extended Data Fig. 7a-f). OI also decreased IL-1β  mRNA in 
BMDMs treated with the TLR2 and TLR3 ligands, Pam3CSK and poly I:C, respectively 
(Extended Data Fig. 7g). LPS-induced ROS, nitric oxide (NO) and iNOS levels were 
limited by OI (Fig. 3c, d and Extended Data Fig. 7h, i). These effects are likely to be a 
consequence of ROS detoxification following Nrf2 induction by OI. IL-1β  and TNF-α 
were decreased by OI in human PBMCs (Fig. 3e, Extended Data Fig. 7j). OI also 
counteracted the pro-inflammatory response to LPS in vivo. OI, which activated Nrf2 
(Extended Data Fig. 7k), prolonged survival, decreased clinical score and improved 
body temperature regulation, and decreased IL-1β  and TNF-α levels but not IL-10 in 
an LPS lethality model (Fig. 3f, g and Extended Data Fig. 8f).   
OI induction of Hmox1 was blocked in Nrf2-deficient macrophages (Fig. 3h 
(compare lanes 2, 3 to lanes 8, 9) and Extended Data Fig. 8f) or when Nrf2 was 
silenced (Extended Data Fig. 8a, d (compare lanes 7, 8 to lanes 11, 12)). Without Nrf2, 
the decrease in LPS-induced IL-1β with OI was significantly impaired (Fig. 3h (compare 
lane 6 to lane 12), Extended Data Fig. 8f and 8b-e (compare lanes 6 and 8 to 10 and 
12)). Furthermore, two Nrf2 activators, diethyl maleate (DEM) and 15deoxy-Δ12,14-
prostaglandin J2 (J2) decreased LPS-induced IL-1β, IL-10, Nos2 and NO (Extended 
Data Fig. 8g-k). Thus, itaconate activates an anti-inflammatory programme through 
Nrf2.   
We next investigated how switching from a pro- to an anti-inflammatory state 
might affect itaconate production from aconitate by Irg1. By modelling gene networks 
controlling Irg1 expression, Tallam and colleagues (2016) identified IFN response 
factor (Irf1) as a regulator18. Here we show that itaconate levels are increased following 
IFN-β treatment (Fig. 4a), in agreement with others19. Levels of citrate and aconitate, 
the substrate for Irg1, were reduced by IFN-β as was the downstream metabolite α-
ketoglutarate (α-KG) (Extended Data Fig. 9a). These data are consistent with an 
increase in aconitate conversion to itaconate rather than α-KG. IFN-β enhanced basal 
and LPS-induced Irg1 expression (Fig. 4b). LPS and poly I:Cinduced Irg1 expression 
in BMDMs lacking type I IFN receptor was decreased (Fig. 4c), indicating that autocrine 
IFN facilitates Irg1 induction. OI limited the IFN response, decreasing IFN-β and IFN-
stimulated gene (ISG)20 expression and Ikappa-B kinase (IKK)-ε  and ISG15 protein, 
IFN-β production in poly I:C-treated PBMCs and LPS-induced IFN-β production in vivo 
(Fig. 4d-g and Extended Data Fig. 9b, c). IFN-β enhanced IL-10 mRNA and protein 
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expression ± LPS (Extended Data Fig. 9d), suggesting that the decrease in IL-10 
following OI treatment is due to reduced type I IFN production 20. Nrf2 knock-out or 
knockdown attenuated the reduction of ISG20 expression by OI while the Nrf2 
activators, DEM and J2, reduced ISG20 expression (Extended Data Fig. 9e-g). This 
agrees with increased expression of IRF3-regulated genes in LPS-treated Nrf2-
deficient mice21.   
These data suggest the operation a negative feedback loop: itaconate is 
generated in response to LPS, in part through type I IFNs, and promotes an 
antiinflammatory programme by Nrf2 activation (Fig. 4h), as well as SDH inhibition3,22. 
This limits further inflammatory gene expression and its own production by 
downregulating the IFN response. This helps explain why Nrf2-deficient mice are more 
sensitive to septic shock21, even though under certain circumstances these mice are 
protected from inflammation23. Our identification of itaconate as an inflammatory 
regulator, that directly modifies proteins through a newly identified post-translational 
modification, unveils therapeutic opportunities to use itaconate or OI to treat 
inflammatory diseases24. Most recently Shen and colleagues (2017) have made an 
intriguing link from itaconate to Vitamin B12 which warrants further investigation in the 
context of inflammation and immunity25. Further understanding the role of itaconate as 
an anti-inflammatory metabolite and regulator of type I IFNs is likely to yield new 
insights into the pathogenesis of inflammatory diseases.  
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Figure Legends   
  
Figure 1. Itaconate activates Nrf2. a-c LPS-induced itaconate (a, n=12, 4 h; b, c n=5, 
24 h). Red and blue dots represent metabolites significantly up- or downregulated by 
LPS, respectively. d Reactivity of itaconate with Keap1 thiol group. e, g LPS-induced 
Nrf2 (e, 24 h) and Hmox1 (e, 6 h) ± OI. f Nrf2 target gene expression ± LPS (6 h) ± OI 
(Nqo1, Gclm, Hmox1 n=12; Gsr, 6Pdg, Taldo1 n=6). h NQO1 activity in Hepa1c1c7 
cells treated as indicated (48 h, n=8). Data are mean ± s.e.m. P values calculated 
using one-way ANOVA. Blots are representative of 3 independent experiments. In the 
box plots, line shows mean. For gel source data, see Supplementary Figure 1.  
  
Figure 2. Itaconate alkylates cysteines. a Itaconate transport by the indicated 
carriers (n=4). b Nrf2 and Keap1 protein following co-transfection with Nrf2-V5 ± 
wildtype or Cys151S mutant Keap1. c MS/MS spectrum of Cys151-containing Keap1 
peptide following OI treatment. d Metabolite tracing to itaconate-cysteine adduct ± LPS 
(24 h, n=5). e Ldha Cys84 alkylation ± LPS (24 h) or OI (250 µM, 4 h) (n=4). Data are 
mean ± s.e.m or S.D. (in a). P values calculated using one-way or two-way ANOVA for 
multiple comparisons or two-tailed student t-test for paired comparisons.  
Blots are representative of 3 independent experiments. For gel source data, see 
Supplementary Figure 1.  
  
Figure 3. OI limits IL-1β in an Nrf2-dependent manner and protects against LPS 
lethality. a-d LPS (24 h), induced IL-1β mRNA (a, n=3), IL-1β and HIF-1α protein (b), 
and ROS and NO production (c, d, n=3, MFI, mean fluorescence intensity) ± OI. e IL-
1β mRNA in PBMCs treated as in a-d (n=3). f Survival, clinical score and body 
temperature measurements in mice (n=10) injected i.p ± OI (50 mg/kg, 2 h) ± LPS (15 
mg/kg). g Serum IL-1β and TNF-α from mice i.p. injected ± OI (50 mg/kg, 2 h) ± LPS 
(2.5 mg/kg, 2 h, n=3 vehicle, OI; n=15 LPS, OI+LPS). h Nrf2, Hmox1 and IL-1β protein 
in wild-type and Nrf2 KO BMDMs treated with LPS (6 h) ± OI. Data are mean ± s.e.m. 
P values calculated using one-way ANOVA. Blots are representative of 3 independent 
experiments. For gel source data, see Supplementary Figure 1.  
  
Figure 4. A feedback loop exists between itaconate and IFN-β. a Metabolite levels 
± IFN-β (1000 U/ml; 27 h; n=5). b LPS (24 h)-induced Irg1 expression ± IFN-β (1000 
U/ml; n=3). c Irg1 expression in wild-type (WT) and IFN receptor (IFNR)deficient 
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BMDMs ± LPS or poly I:C (40 µg/ml) for 24 h (n=3). d IFN-β (n=3) expression ± LPS 
(24 h) ± OI. e ISG15 and IKK-ε ± LPS (24 h) ± OI. f IFN-β protein expression in PBMCs 
± poly I:C (20 µg/ml; 24 h) ± OI (n=3). g Serum IFN-β from mice i.p. injected ± OI (50 
mg/kg, 2 h) ± LPS (2.5 mg/kg; 2 h) (n=3 vehicle, OI; n=15 LPS, OI+LPS). h The anti-
inflammatory role of itaconate. Data are mean ± s.e.m. P values calculated using one-
way ANOVA. Blots are representative of 3 independent experiments. f is 
representative from one of two human donors. For gel source data, see Supplementary 
Figure 1.  
METHODS  
  
Isolation of Human PBMC  
Human PBMC were isolated from human blood using Lymphoprep (Axis-Shield). 30 
ml of whole blood was layered on 20 ml lymphoprep and spun for 20 min at 2,000 rpm 
with no brake on. The PBMCs were isolated from the middle layer. PBMCs were 
maintained in RPMI supplemented with 10% (vol/vol) FCS, 2 mM L-glutamine, and 1% 
penicillin/streptomycin solution.  
  
Generation of human macrophages  
Blood was layered on Histopaque and centrifuged at 800 x g for 20 minutes, 
acceleration 9, deceleration at 4. The PBMC layer was isolated and the macrophages 
were sorted using magnetic-activated cell sorting (MACS) CD14 beads Cells were 
plated at 0.5 x 106 cells/ml in media containing M-CSF (100 ng/ml) and maintained at 
37°C, 5% CO2 for 5 days, to allow differentiation into macrophages. For further details 
see the Supplementary Methods section.  
  
Generation and treatment of bone marrow-derived macrophages (BMDMs) Mice 
were euthanized in a CO2 chamber and death was confirmed by cervical dislocation. 
Bone marrow cells were extracted from the leg bones and differentiated in DMEM 
(containing 10% foetal calf serum, 1% penicillin streptomycin and 20% L929 
supernatant) for 6 days, at which time they were counted and replated for experiments. 
Unless stated, 5 X 106 BMDMs/ml were used in in vitro experiments. Unless stated the 
LPS concentration used was 100 ng/ml, the DMI and OI concentration was 125 µM 
and in experiments were pre-treatments prior to LPS stimulation this was for 3 h.   
  
Synthesis of Itaconate compounds  
For details on synthesis and characterization of chemical compounds details see 
Supplementary Methods.  
  
Metabolomic analysis with Metabolon    
Macrophages were plated at 2x106/well in 6-well plates and treated as required 
BMDMs, n=5, human macrophages n=12. Analysis was performed by Metabolon. For 
further details see the Supplementary Methods section.   
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Metabolite Measurements for absolute succinate and itaconate quantification 
and metabolite tracing  
Cells were treated as desired. For tracing studies, immediately prior to LPS stimulation 
the media was removed and replaced with DMEM media (1 ml) containing U-13C-
glucose (4.5 g/L) or U-13C-glutamine (584 mg/mL) deplete of 12C- glucose or 12C-
glutamine. Samples were extracted in methanol/acetonitrile/water, 50:30:20 v/v/v (1 ml 
per 1x106 cells) and agitated for 15 min at 4°C in a Thermomixer and then incubated 
at -20°C for 1 h. Samples were centrifuged at maximum speed for 10 min at 4°C. The 
supernatant was transferred into a new tube and centrifuged again at maximum speed 
for 10 min at 4°C. The supernatant was transferred autosampler vials. LC-MS analysis 
was performed using a Q Exactive mass spectrometer coupled to a Dionex U3000 
UHPLC system (Thermo). For further details see Supplementary Methods.  
  
Western blotting  
Protein samples from cultured cells were prepared by direct lysis of cells in 5X Laemmli 
sample buffer, followed by heating at 95°C for 5 min. For spleen samples, 30 mg of 
spleen was homogenized in RIPA buffer using the Qiagen TissueLyserII system. The 
resulting homogenate was centrifuged at 14000 rpm for 10 min at 4°C, and 
supernatants were used for SDS-PAGE. Protein samples were resolved on 8% or 12% 
SDS-PAGE gels and were then transferred onto polyvinylidene difluoride (PVDF) 
membrane using either a wet or semi-dry transfer system. Membranes were blocked 
in 5% (w/v) dried milk in Tris-buffered saline-Tween (TBST) for at least one hour at 
room temperature. Membranes were incubated with primary antibody, followed by the 
appropriate horseradish peroxidase-conjugated secondary antibody. They were 
developed using LumiGLO enhanced chemiluminescent (ECL) substrate (Cell 
Signalling). Bands were visualized using the GelDoc system (Biorad).  
  
Real-time PCR  
Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen) and quantified using 
a Nanodrop 2000 UV-visible spectrophotometer. cDNA was prepared using 20–100 
ng/µl total RNA by a reverse transcription-polymerase chain reaction (RT-PCR) using 
a high capacity cDNA reverse transcription kit (Applied Biosystems), according to the 
manufacturer’s instructions. Real-time quantitative PCR (qPCR) was performed on 
cDNA using SYBR Green probes. qPCR was performed on a 7900 HT Fast RealTime 
PCR System (Applied Biosystems) using Kapa fast master mix high ROX (Kapa 
Biosystems, for SYBR probes) or 2X PCR fast master mix (Applied Biosystems, for 
Taqman probes). For SYBR primer pair sequences see Supplementary Methods. Fold 
changes in expression were calculated by the Delta Delta Ct method using mouse 
Rps18 as an endogenous control for mRNA expression. All fold changes are 
expressed normalized to the untreated control.  
  
NQO1 bioassay  
Inducer potency was quantified by use of the NQO1 bioassay in Hepa1c1c7 murine 
hepatoma cells 11,12. Cells (104 per well of a 96-well plate) were grown for 24 h and 
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treated (n=8) to serial dilutions of compounds for 48 h prior to lysis. NQO1 enzyme 
activity was quantified in cell lysates using menadione as a substrate. Protein 
concentrations were determined in aliquots from the same cell lysates by the 
bicinchoninic acid (BCA) assay (Thermo Scientific). The CD value was used as a 
measure of inducer potency. For assays examining the effect of GSH on inducer 
potency, 50 µM of each compound was incubated with 1 mM GSH in the cell culture 
medium at 37°C for 30 min before treatment.  
  
Preparation of rat liver mitochondria  
Female Wistar rats aged between 10 to 12 weeks (Charles River, UK) were culled by 
stunning and cervical dislocation prior to the liver being excised and stored in icecold 
buffer (STE buffer (250 mM sucrose, 5 mM Tris-Cl, 1 mM EGTA (pH 7.4 at 4 °C)). Rat 
liver mitochondria were isolated by homogenisation and differential centrifugation at 
4°C in STE buffer26. Briefly, minced tissue was homogenised in STE buffer before 
centrifugation (1, 000 x g, 3 min, 4°C) and centrifuging the resulting supernatant (10, 
000 x g, 10 min, 4°C). The mitochondrial pellet was resuspended in fresh STE before 
centrifuging (10, 000 x g, 10 min, 4°C). The resulting pellet was resuspended in STE 
and assayed for protein concentration via BCA assay (Thermo Scientific) against a 
BSA standard curve.   
  
Preparation of bovine heart mitochondrial membranes  
Bovine heart mitochondria were isolated by differential centrifugation in 250 mM 
sucrose, 10 mM Tris-Cl, 0.2 mM EDTA (pH 7.8 at 4°C). To prepare membranes, bovine 
heart mitochondria were blended with MilliQ water at 4°C before adding KCl to a final 
concentration of 150 mM and blending until homogenous. The suspension was 
centrifuged (13, 500 x g, 40 min, 4°C) and the pellet resuspended in resuspension 
buffer (20 mM Tris-Cl, 1 mM EDTA, 10% glycerol, pH 7.55 at 4°C) before 
homogenisation and assaying for protein by BCA assay (Thermo Scientific)27.  
  
Measuring complex II+III activity  
Bovine heart mitochondrial membranes (80 µg protein/ml) were incubated in 50 mM 
potassium phosphate buffer (50 mM potassium phosphate, 1 mM EDTA, pH 7.4, 4°C) 
supplemented with 3 mM KCN, 4 µM rotenone and succinate. In a 96-well microplate, 
inhibitor or vehicle control and membrane incubation were plated and incubated for 10 
minutes at 30°C. Alternatively, where indicated, itaconate was incubated with 
membranes and removed by twice centrifuging membranes and resuspending in non-
itaconate containing buffer, prior to plating with 1 mM succinate. Oxidised cytochrome-
c was added prior to measuring the respiratory chain activity by assessing the 
reduction of cytochrome-c spectrophotometrically at 550 nm at 20 second intervals for 
5 min at 30°C. Final concentrations were 10 µg protein/well bovine heart membranes 
and 30 µM ferricytochrome c.  
  
Measuring rat liver mitochondrial respiration  
Respiration of rat liver mitochondria was assessed with an Oxygraph-2K (OROBOROS 
instruments high resolution respirometry, Austria). Rat liver mitochondria (0.5 mg 
mitochondrial protein/ml) were added to KCl buffer (pH 7.2, 37°C) and respiration 
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assessed in the presence of 4 µg/ml rotenone, 1 mM succinate, 1 µM FCCP and 
inhibitors or buffer control.  
  
Assessing itaconate ester reactivity with glutathione  
1 or 5 mM GSH and 5 mM itaconate esters or vehicle control were incubated in KCl 
buffer (pH 7.2 or 8) at 37°C for 2 hours, where indicated, 10 µg recombinant 
glutathione-S-transferase (GST) was added to the incubation. The reaction was 
stopped by acidification with 5% sulfosalicylic acid prior to assessing glutathione 
content by the GSH recycling assay as described previously 28.  
  
Itaconate transport assays  
Itaconate transport by mitochondrial carriers was assessed as described previously 29. 
For further details see the Supplementary Methods section.   
  
Cell uptake of itaconate  
C2C12 mouse myoblasts were plated at 300,000 cells/well in a 6-well plate in complete 
growth medium and adhered overnight in a humidified 5% CO2, 37°C incubator. The 
following day, media was replaced with serum free DMEM containing itaconate esters 
and cells were treated for 30 minutes at 37°C. Cells were extracted as described above 
(method for succinate quantification), with MS internal standard (100 pmoles) added 
and stored at -80°C prior to LC-MS/MS analysis. For further details see Supplementary 
Methods.  
  
LC-MS/MS analysis was performed using an LCMS-8060 mass spectrometer 
(Shimadzu) with a Nexera X2 UHPLC system (Shimadzu). For further details see  
Supplementary Methods  
  
Keap1 cysteine target validation   
COS1 cells (2.5 x 105 per well) in 6-well plates were co-transfected (Lipofectamine 
2000) with 0.8 µg of Nrf2-V5 and 1.6 µg of wild-type or Cys151S mutant Keap114, or 
1.6 µg of pcDNA. Cells were grown for 21 h then treated with 20 or 100 µM OI, 5 µM 
sulforaphane (SFN) or 0.1% acetonitrile (ACN, vehicle) for 3 h. Cell were washed in 
PBS and lysed in 200 µl of SDS-lysis buffer [50 mM Tris-HCl pH 6.8, 2% (w/v) sodium 
dodecyl sulfate (SDS) and 10% (v/v) Glycerol]. Lysates were sonicated (20 sec at 30% 
amplitude using Vibra-Cell ultrasonic processor, Sonic) and boiled (3 min), DTT and 
Bromophenol blue were added up to 0.1M and 0.02% (w/v) final concentrations, 
respectively. Proteins (10 µg) were resolved on a gradient (4-12%) NuPAGE SDS gel, 
transferred onto nitrocellulose membranes, and immunoblotted with anti-Keap1 (rat 
monoclonal, Merk Millipore, clone 144), anti-Nrf2 (rabbit monoclonal, CST), and anti-
β -actin (mouse monoclonal, Sigma) antibodies. HRP- or IRDye-labelled secondary 
antibodies were used interchangeably, followed by either ECL-detection or scanning 
using Odyssey imager (Li-COR).     
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Enzyme-linked immunosorbent assay (ELISA)  
Cytokine concentrations in cell supernatants were measured using enzyme-linked 
immunosorbent assay (ELISA) Duoset kits for mouse IL-10 and TNF-α and human 
IFN-β and IL-1β, according to the manufacturer’s instructions. Cytokine concentrations 
in serum samples isolated from whole blood were measured using Quantikine ELISA 
kits for mouse or human IL-1β, IFN-β IL-10 and TNF-α. Duoset and Quantikine kits 
were from R&D Systems. Optical density values were measured at a wavelength of 
450 nm, using a FLUOstar Optima plate reader (BMG Labtech). Concentrations were 
calculated using a 4-parameter fit curve.   
  
FACS Analysis of reactive oxygen species (ROS)  
BMDMs were seeded at 0.5x106 cells/ml and treated as normal. 2 hours prior to 
staining, 100% EtOH was added to the dead cell control well. 30 minutes prior to the 
end of the stimulation, CellROX (5 µM) was added directly into the cell culture medium. 
Supernatants of cells that were to be stained with Aqua Live/Dead were removed, and 
an Aqua Live/Dead dilution (1 ml; 1 in 1000 in PBS) was added to each well. Cells 
were incubated in tinfoil at 37°C for 30 min. Cells were washed with PSB, scraped in 
PBS (0.5 ml), and transferred to polypropylene FACS tubes. Samples were analyzed 
using a Dako CyAn flow cytometer, and data was analyzed using FlowJo software. 
Mean fluorescence intensity (MFI) was quantified as a measure of cellular ROS 
production.  
  
NO assay  
Nitric oxide concentrations in cell supernatants were measured using Greiss reagent 
assay kit from Thermo Fischer Scientific according to the manufacturer’s instructions. 
Optical density values were measured at a wavelength of 548 nm, using a SoftMax 
Pro plate reader. Concentrations were calculated using a linear standard curve.  
  
GSH/GSSG measurements  
BMDMs were plated at 0.1x106 cells/ml in opaque 96-well plates. Cells were pretreated 
with OI (125 µM) for 2 h and then stimulated with H2O2 (100 µM) for 24h. After 24 h 
cell media was removed and GSH/GSSG was quantified using MyBio GSH/GSSG-Glo 
Assay (V6611) as per manufacturer’s instructions. Luminescence was quantified using 
a FLUOstar Optima plate reader.  
  
LDH assay  
Cells were plated at 0.5x106 cells/ml in white 24-well plates (500 µl/well) and treated 
as required. Cytotoxicity, as determined by LDH release, was assayed using 
CytoTox96 Non-radioactive Cytotoxicity Assay kit (Promega) according to the 
manufacturer’s instructions.  
  
Seahorse analysis of lactate production  
Cells were plated at 0.2x106 cells/well of a 24-well Seahorse plate. Cells were treated 
and stimulated as normal. A utility plate containing calibrant solution (1 ml/well) was 
placed in a CO2-free incubator at 37°C overnight. The following day media was 
removed from cells and replaced with glucose-supplemented XF assay buffer (500 
  { PAGE   \* MERGEFORMAT }  
µl/well) was placed in a CO2-free incubator for at least 0.5 h. Inhibitors (Oligomycin, 
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), 2DG, Rotenone; 70 
µl) were added to the appropriate port of the injector plate. This plate together with the 
utility plate was run on the Seahorse for calibration. Once complete, the utility plate 
was replaced with the cell culture plate and run on the Seahorse XF-24.    
  
Endotoxin-induced model of sepsis  
For cytokine measurements mice were treated intraperitoneally (i.p.) ± OI (50 mg/kg) 
in 40% cyclodextrin in PBS or vehicle control for 2 h prior to stimulation with LPS 
(Sigma; 2.5 mg/kg) i.p. for 2 h. Mice were euthanized in a CO2 chamber, blood samples 
were collected and serum was isolated. Cytokines were measured using R&D ELISA 
kits according to manufactures protocol. For temperature recording mice (n=10 per 
group) were treated i.p. ± OI (50 mg/kg) in 40% cyclodextrin in PBS or vehicle control 
for 2 h prior to stimulation with LPS (5 mg/kg) and monitored for temperature at 1, 2, 
3, 4, 6, 12, 18 and 24 hours post LPS. Temperature was monitored using 
subcutaneously implanted temperature transponder chips (Bio Medic Data Systems; 
IPTT 300) which were injected between the shoulder blades 48 hours prior to 
experiment. At defined time body temperature was measured by scanning the 
transponder with a corresponding BMDS Smart Probe. Animals were additionally 
monitored for clinical signs of endotoxic shock, based on temperature change, body 
condition, physical condition and unprovoked behavior, with a combined score of 9 
indicating the humane end point for the experiment.  
  
siRNA transfection of BMDMs  
Cells were plated at 1x106 cells/ml in 12 well plates overnight. On the day of 
transfection the media was replaced with 500 µl DMEM without P/S or FBS. Two 
eppendorfs/siRNA were prepared. Optimem (250 µl/well) was added to each tube. 
RNAimax (add 5 µl/well) was added to one set of tubes and siRNA (50 nM/well) was 
added to the second set of tubes. The tubes containing the siRNA was added to the 
tube with RNAimax, mixed well by pipetting and incubated for 15 min. The mix (500 µl) 
was added to each well. 24 h post transfection cells were treated as required.   
  
Analysis of Keap1 modification by OI  
Human embryonic kidney cells (HEK293Ts) were transfected with a pCMV6-Keap1 
vector (Myc-DDK-tagged mouse Keap1) (OriGene). 24 h post-transfection, cells were 
treated with OI (500 µM) or vehicle control (PBS) for 4 h. Tagged-Keap1 was 
immunoprecipitated using an anti-FLAG antibody (Sigma) and protein A/G beads 
(Santa Cruz). After immunoprecipitation, bound Keap1 was eluted off the beads using 
FLAG peptide (500 µl; 200 µg/ml) (Sigma) diluted in 1X TBS pH 7.4. The samples were 
then concentrated and the FLAG peptide removed using 10K centrifugation filter 
columns (Merck). The concentrated samples were then divided in half for downstream 
processing. One half of each sample was diluted 1 in 2 with 5X SDS sample buffer and 
separated using SDS-PAGE (Bio-Rad). Overexpressed Keap1 was detected using 
Coomassie blue staining and the corresponding bands were excised from the gel and 
subjected to in-gel digest as described. Briefly, the gel slices were cut into smaller 
pieces (1-2 mm3) prior to reduction with DTT (10 mM) and alkylation with IAA (50 mM). 
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Half of the gel slices from each sample were then subjected to a trypsin (2 µg) digest, 
the other half were digested with elastase (1 µg) overnight at 37°C. Similarly, the 
remaining sample concentrates (in solution) were reduced with DTT and alkylated with 
IAA, prior to precipitation of the protein via the methanol-chloroform extraction method. 
The protein pellet was re-suspended in urea (6 M), which was then diluted to <1 M 
urea with ultrapure H2O. The samples were then digested with trypsin (2 µg) overnight 
at 37°C. Digested protein samples were analysed in an Orbitrap Fusion Lumos coupled 
to a UPLC ultimate 3000 RSLCnano System (both Thermo Fisher). For further details 
see Supplementary Methods.  
  
Assessment of cysteine alkylation by itaconate using Iodo-TMT  
Following treatment cells were lysed in HEPES pH 7.5, EDTA, glycerol and NP40. 2 
mM TCEP and 50 mM NEM were added in a buffer containing 50 mM HEPES, 2% 
SDS, 125 mM NaCl, pH 7.2 and samples were incubated for 60 min at 37 °C in the 
dark to reduce and alkylate all unmodified protein cysteine residues. 20% (v/v) TCA 
was added to stabilize thiols and incubated overnight at 4°C and then pelleted for 10 
min at 4000 g at 4 °C. The pellet was washed with 3 times with cold methanol (2 ml) 
and then resuspended in 2 ml 8 M urea containing 50 mM HEPES (pH 8.5). Protein 
concentrations were measured by BCA assay (Thermo Scientific) prior to protease 
digestion. Protein lysates were diluted to 4 M urea and digested with LysC (Wako, 
Japan) in a 1/100 enzyme/protein ratio and trypsin (Promega) at a final 1/200 
enzyme/protein ratio for 4 hours at 37 °C. Protein extracts were diluted further to a  
2.0 M urea and LysC (Wako, Japan) at 1/100 enzyme/protein ratio and trypsin 
(Promega) at a final 1/200 enzyme/protein ratio were added again and incubated 
overnight at 37 °C. Protein extracts were diluted further to a 1.0 M urea concentration, 
and trypsin (Promega) was added to a final 1/200 enzyme/protein ratio for 6 hours at 
37 °C. Digests were acidified with 250 µL of 25% acetic acid to a pH ~2, and subjected 
to C18 solid-phase extraction (50 mg Sep-Pak, Waters). 6-7 M excess TMT label was 
added to each digest for 30 min at room temperature (repeated twice). The reaction 
was quenched using 4 uL of 5% hydroxylamine.  
Samples were subjected to an additional C18 solid-phase extraction (50 mg SepPak, 
Waters). For LC-MS/MS parameters, Data processing and MS2 spectra assignment, 
TMT reporter ion intensities and quantitative data analysis see Supplementary 
Methods.   
  
Reagents  
For a complete list of reagents see Supplementary Methods.   
  
Mouse strains   
Wild type C57Bl/6 mice were from Harlan U.K. and Harlan Netherlands. Animals were 
maintained under specific pathogen-free conditions in line with Irish and European 
Union regulations. Experiments were approved by local ethical review and were carried 
out under the authority of Ireland’s project license. All animal studies performed in GSK 
were ethically reviewed and carried out in accordance with Animals (Scientific 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of 
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Animals.” Nrf2-deficient mice and their wild type counterparts, both on the C57Bl/6 
genetic background (used for isolation of BMDM cells) were bred and maintained in 
the Medical School Resource Unit of the University of Dundee.  
  
Statistical analysis  
Data were expressed as mean ± s.e.m. and P values were calculated using twotailed 
Student’s t-test for pairwise comparison of variables, one-way ANOVA for multiple 
comparison of variables, and two-way ANOVA involving two independent variables. A 
Sidak’s multiple comparisons test was used. A confidence interval of 95% was used 
for all statistical tests. Sample sizes were determined on the basis of previous 
experiments using similar methodologies. For all experiments, all stated replicates are 
biological replicates. For in vivo studies, mice were randomly assigned to treatment 
groups. For MS analyses, samples were processed in random order and 
experimenters were blinded to experimental conditions.     
  
Data Availability   
Full scans for all western blots have been provided in the Supplementary Figures. 
Source Data for all mouse experiments have been provided. All other data are 
available from the corresponding author on reasonable request.  
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Extended Data Figure 1. The effect of itaconate on CII activity. a Complex II+III 
activity in bovine heart mitochondrial membranes incubated with succinate ± malonate 
or itaconate (n=3 independent experiments). b Effect of malonate or itaconate on 
oxygen consumption rate of rat liver mitochondria in the presence of succinate (1 mM) 
and FCCP (1 µM; n=3 independent experiments). c, d Complex II+III activity in bovine 
heart mitochondrial membranes incubated with itaconate (1 mM unless indicated), with 
subsequent removal and addition of succinate (1 mM; n=3 independent experiments). 
Data are mean ± s.e.m, n=3 independent experiments. P values calculated using one 
or two-way ANOVA.  
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Extended Data Figure 2. DMI activates Nrf2 and limits cytokine production. a, c 
LPS (100 ng/ml)-induced Nrf2 (a, 24 h) and Hmox1 (c, 6 h) protein expression ± DMI. 
b Nrf2-dependent mRNA expression ± LPS (6 h) ± DMI (n=3). d GSH and GSSG levels 
± LPS ± DMI (n=5). e, f LPS (24 h)-induced IL-1β mRNA (e), IL-1β and HIF-1α protein 
(f) expression ± DMI (n=3). Data are mean ± s.e.m. P values calculated using one-way 
ANOVA. Blots are representative of 3 independent experiments. For gel source data, 
see Supplementary Figure 1.  
  
Extended Data Figure 3. OI is the best tool to assess itaconate-dependent Nrf2 
activity. a Reactivity of DMI, itaconate and OI with thiols. b, c Itaconate ester reactivity 
with GSH ± GST as detailed in Methods (n=3). d Itaconate levels in C2C12 cells ± 
itaconate esters (n=3). e, i Itaconate or GSH levels ± LPS (6 h) ± OI (n=5). f NQO1 
activity in Hepa1c1c7 cells treated with DMI or OI (48 h) ± GSH (n=8). g, h Metabolic 
intermediates in glutathione (GSH) synthesis (h, average of 5 biological replicates). i 
GSH levels ± LPS (6 h) ± OI (n=5). j GSH/GSSG ± OI (2 h) ± H2O2 (100 µM, 24 h; 
n=3). k Hmox protein levels ± OI ± H2O2 (24 h). l Nrf2, Hmox and IL-1β protein levels 
in BMDMs pre-treated with OI, 4-octyl 2-methylsuccinate (OMS) or octyl succinate 
(OS), all 125 µM for 3 h ± LPS (6 h). m LPS-induced Nrf2 (24 h) and Hmox1 (6 h) 
protein expression ± dimethyl malonate (DMM). Data are mean ± s.e.m. P values 
calculated using one- or two-way ANOVA. Blots are representative of 3 independent 
experiments. For gel source data, see Supplementary Figure 1.  
  
Extended Data Figure 4. Itaconate is transported by the mitochondrial 
oxoglutarate, dicarboxylate and citrate carriers. a Itaconate uptake into vesicles of 
Lactococcus lactis membranes expressing indicated carriers loaded with itaconate (1 
mM), and transport initiated by the addition of [3H]-itaconate (1 µM). b Initial transport 
rates of each carrier with either canonical substrate (homo-exchange) or canonical 
substrate/itaconate (hetero-exchange). Results are presented as n=4 independent 
experiments ± S.D. P values calculated using 2-tailed student t-test.   
  
Extended Data Figure 5. Keap1 is alkylated by OI on major redox sensing 
cysteines. a Modification of cysteine by fumarate or itaconate. MS/MS spectrum of 
Keap1 Cys257 (b), Cys257 (c) and Cys288 (d) peptides indicating alkylation of these 
sites with OI treatment (left) but not in the corresponding carbamidomethylated (CAM) 
peptides (right). e, f Ldha Cys84 alkylation ± LPS (e, 24 h) or OI (f, 250 µM, 4 h) (n=4). 
Detected N- and C-terminal fragment ions of both peptides are assigned in the 
spectrum and depicted as follows: b: N-terminal fragment ion; y: C-terminal fragment 
ion; *: fragment ion minus NH3; 0 or *: fragment ion minus H2O; and 2+: doubly charged 
fragment ion. Representative of 1 independent experiment.  
  
Extended Data Fig 6. Identification of an itaconate-cysteine adduct. 13C6-glucose 
(a-c) or 13C5-glutamine (d-e) labelling experiment tracking itaconate-cysteine adduct 
formation in BMDMs treated with LPS (n=5; 24 h). b, e represent % isotopologue of 
the total pool. c, f represent changes in the total pool ± LPS treatment. Data are mean 
± s.e.m, for 5 replicates. P values calculated using two-way ANOVA.  
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Extended Data Figure 7. OI decreases LPS-induced cytokine production, ECAR, 
ROS and NO. a % cytotoxicity in BMDMs ± LPS ± OI (n=3). b LPS-induced ECAR ± 
OI, analysed on the Seahorse XF-24 in BMDMs (representative trace of n=3). c, d 
LPS-induced IL-10 mRNA (c, 4 h) and protein (d, 24 h) and TNF-α protein (f; n=7) ± 
OI (n=3). e pp65 protein levels ± LPS ± OI. h Representative gating strategy for FACS 
analysis of ROS production in cells as treated in d (representative image of n=3). i 
LPS-induced Nos2 expression (n=6) ± OI. j LPS-induced TNF-α (n=4) and IL-1β (n=3) 
protein levels ± OI in PBMCs. k Nrf2 and hmox1 protein levels (m=mouse) or Nrf2-
dependent gene expression (n=5) in peritoneal macrophages from mice i.p. injected ± 
OI (50 mg/kg, 6 h). l Serum IL-10 from mice i.p. injected ± OI (50 mg/kg, 2 h) ± LPS 
(2.5 mg/kg, 2 h, n=3 vehicle, OI; n=15 LPS, OI+LPS). Data are mean ± s.e.m. P values 
calculated using one-way ANOVA. Blots are representative of 3 independent 
experiments. For gel source data, see Supplementary Figure 1.  
  
Extended Data Figure 8. The effects of OI on cytokine production are Nrf-
2dependent. a-e: Nrf2, Hmox1, IL-1β protein (a, c, d) and IL-1β mRNA (b, e) 
expression in BMDMs transfected with two different Nrf2 (50 nM) siRNAs compared 
with non-silencing control ± LPS (6 h; a, b, d) or (24 h; c, d, e) ± OI (n=6). f IL-1β 
mRNA expression in wild-type and Nrf2 KO BMDMs treated with LPS (24 h; WT (n=2) 
and Nrf2 KO (n=4)) ± OI. IL-1β (g), Nos2 (j) mRNA and IL-1β (h), IL-10 (i),  
TNF-α and NO (k) protein ± LPS (24 h) ± diethyl maleate (DEM; 100 µM) or 15Deoxy-
Δ12,14-prostaglandin J2 (J2; 5 µM) pretreatment for 3 h (n=3). Data are mean ± s.e.m. 
P values calculated using one-way ANOVA. Blots are representative of 3 independent 
experiments. For gel source data, see Supplementary Figure 1.   
  
Extended Data Figure 9. An Nrf2-dependent feedback loop exists between 
itaconate and IFN-β. a Metabolite levels ± IFN-β (1000 U/ml; 27 h; n=5). b, c Isg20 
and Irf5 mRNA expression in BMDMs treated with LPS (b) or poly I:C (c, 40 µg/ml; 24 
h) ± OI (n=6). d IL-10 mRNA (n=3) and protein (n=5) expression ± LPS for 4 h (left 
panel) or 24 h (right panel) ± IFN-β treatment (1000 U/ml) for 3 h. e Isg20 expression 
in BMDMs transfected with two different Nrf2 (50 nM) siRNAs compared with non-
silencing control ± LPS (6 h) ± OI (n=6). f ISG20 mRNA expression in WT (n=2) and 
Nrf2 KO (n=4) BMDMs ± LPS (6 h) ± OI. g ISG20 mRNA expression ± LPS (24 h) ± 
diethyl maleate (DEM; 100 µM) or 15-Deoxy-Δ12,14-prostaglandin J2 (J2; 5 µM) 
pretreatment for 3 h (n=3). Data are mean ± s.e.m, P values calculated using one-way 
ANOVA.  
  
Extended Data Table 1. Mass spectrometry analysis of itaconate-induced cysteine 
alkylation. a Cysteine/Lysine Residue(s) in Keap1 modified by OI as determined by 
tandem mass spectrometry. b Cysteine residues modified by itaconate in BMDMs 
treated with LPS identified using tandem mass spectrometry. c Cysteine residues 
modified by itaconate in BMDMs treated with OI identified using tandem mass 
spectrometry  
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Extended Data Figure 1. The effect of itaconate on CII activity. a Complex II+III activity in bovine heart mitochondrial 
membranes incubated with succinate ± malonate or itaconate (n=3). b Effect of malonate or itaconate on oxygen 
consumption rate of rat liver mitochondria in the presence of succinate (1 mM) and FCCP (1 µM; n=3). c, d Complex II+III 
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indicated), with 
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succinate (1 
mM; n=3)). Data 
are mean ± 
s.e.m, n=3. 
*P<0.05, 
**P<0.01, 
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****P<0.0001 
one or two-way 
ANOVA.  
**** 
e 
HIF-1α 
 β-actin  
 Extended Data Figure 2. DMI activates Nrf2 and limits cytokine production. a, c LPS (100 ng/ml)-induced Nrf2 (a, 
24 h) and Hmox1 (c, 6 h) protein expression ± DMI pretreatment for 3 h. b Nrf2-dependent mRNA expression in LPS-
stimulated BMDMs (6 h) ± DMI (125 μM) pretreatment for 3 h (n=3). d GSH and GSSG levels in LPS (100 ng/ml)-treated 
BMDMs ± DMI pretreatment for 3 h (n=5). e, f LPS (100 ng/ml, 24 h)-induced IL-1β mRNA (e), IL-1β and HIF-1α protein 
(f) expression ± DMI pretreatment for 3 h in BMDMs (n=3). Data are mean ± s.e.m, of at least 3 replicates. **p<0.01, 
****p<0.0001  one-way ANOVA. Blots are representative of 3 experiments.  
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Extended Data Figure 3. OI is the best tool to assess itaconate-dependent Nrf2 activity. a Schematic of reactivity 
of DMI versus itaconate or OI with thiols. b, c Itaconate ester reactivity with GSH ± GST as detailed in Methods (n=3). d 
LC-MS/MS analysis of itaconate levels in C2C12 cells treated with itaconate esters (n=3). e LC-MS/MS analysis of 
itaconate release following incubation of itaconate esters with porcine liver esterase (n=3). f, h Absolute quantification of 
itaconate levels (f) or relative GSH levels (fold over ctl; h) in BMDMs treated with LPS (100 ng/ml) for 6 h ± OI pretreatment 
for 3 h (n=5). g NQO1 activity in Hepa1c1c7 cells treated with DMI or OI for 48 h ± GSH pre-treatment. NQO1 activity 
was determined as described in Methods (n=8). h GSH/GSSG ratio in BMDMs pre-treated with OI (125 µM) for 2 h and 
then stimulated with H2O2 (100 µM) for 24 h (n=3) as determined using MyBio GSH/GSSG-Glo Assay. i Hmox protein 
levels in BMDMs pre-treated with OI (125 µM) for 3 h and then stimulated with H2O2 for 24 h. j Nrf2, Hmox and IL-1β 
protein levels in BMDMs pre-treated with 4-octyl itaconate (OI), 4-octyl 2-methylsuccinate (MS) or octyl succinate (OS; 
 
k 
 β-actin  
Nrf2 
 β-actin  
Hmox1 
 β-actin  
Hmox1 
Nrf2 
 IL-1β 
j 
 125 µM), for 3 h and then stimulated with LPS (100 ng/ml) for 6 h. k LPS (100 ng/ml)-induced Nrf2 (24 h) and Hmox1 (6 
h) protein expression ± DMM pretreatment for 3 h. Data are mean ± s.e.m of at least 3 replicates. *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001 one- or two-way ANOVA.  
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 Extended Data Figure 4. Itaconate is transported by the mitochondrial oxoglutarate, dicarboxylate and citrate 
carriers. a Itaconate uptake into vesicles of Lactococcus lactis membranes expressing indicated carriers loaded with 
itaconate (1 mM), and transport initiated by the addition of [3H]-itaconate (1 μM). b Initial transport rates of each carrier 
with either canonical substrate (homo-exchange) or canonical substrate/itaconate (hetero-exchange, as indicated in each 
panel. Empty vector control rates are also shown. For details see Methods. Results are presented as n=4 ± S.D. *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 student t-test.   
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Extended Data Figure 5. Keap1 is alkylated by OI on major redox sensing cysteines. MS/MS spectrum of Keap1 
Cys257 (a), Cys257 (b) and Cys288 (c) peptides indicating alkylation of these sites with OI treatment (left) but not in the 
corresponding carbamidomethylated (CAM) peptides (right). Detected N- and C-terminal fragment ions of both peptides 
are assigned in the spectrum and depicted as follows: b: N-terminal fragment ion; y: C-terminal fragment ion; *: fragment 
ion minus NH3; 0: fragment ion minus H2O; and 2+: doubly charged fragment ion.  
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Extended Data Fig 6. Identification of an itaconate-cysteine adduct. a MS/MS spectrum of itconate-cysteine adduct 
in LPS treated macrophages treated with 13C6-glucose (left) or 13C5-glutamine (right). b, c Potential inputs to itaconate-
cysteine adduct formation and 13C-metabolite labelling strategy and 13C6-glucose (b) or 13C5-glutamine (c) profile of Krebs 
cycle intermediates and itaconate-cysteine adduct in BMDMs treated with LPS (100 ng/ml) for 24 h.  
 a b c d 
 
e 
+OI (125 µM)  
pp65 
 β-actin  
f g 
h 
Extended Data Figure 7. OI decreases LPS-induced cytokine production, ECAR, ROS and NO. a % cytotoxicity in  
BMDMs treated with LPS (100 ng/ml) ± OI pretreatment for 3 h at the indicated concentration as determined by LDH (n=3). 
b LPS (100 ng/ml)-induced ECAR ± OI pretreatment for 3 h, analysed on the Seahorse XF-24 in BMDMs (representative 
trace of n=3). c, d LPS (100 ng/ml)-induced IL-10 mRNA (c, 4 h) and protein (d, 24 h) expression ± OI pretreatment (125 
μM; d) for 3h in BMDMs (n=3). e pp65 protein levels in BMDMs pre-treated with OI (125 µM) for 3 h and then stimulated 
with LPS (100 ng/ml) for the indicated times. f Representative gating strategy for FACS analysis. g ROS production in 
cells as treated in d as detailed in Methods. Live cells were analyzed by FACS and mean fluorescence intensity (MFI) 
was quantified as a measure of cellular reactive oxygen species production (representative image of n=3). h LPS (100 
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 ng/ml, 24 h)-induced TNF-α (n=4) and IL-1β (n=3) protein levels ± OI pretreatment for 3 h in PBMCs. Data are mean ± 
s.e.m, of at least 3 replicates. *p<0.05; **p<0.01, ***p<0.001, ****p<0.0001 one-way ANOVA. Blots are representative of 
3 experiments.   
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 Extended Data Figure 8. The effects of OI on cytokine production are Nrf-2-dependent. a-e: Nrf2, Hmox1, IL-1β 
protein (a, c, d) and IL-1β mRNA (b, e) expression in BMDMs transfected with two different Nrf2 (50 nM) siRNAs compared 
with non-silencing control following treatment with LPS for 6 h (a, b, d) or 24 h (c, d, e) ± OI (125 μM) pretreatment for 3h 
(n=6). IL-1β (f), Nos2 (i) mRNA and IL-1β (g), IL-10 (h) and TNF-α protein expression in BMDMs treated with LPS for 24 
h ± diethyl maleate (DEM; 100 μM) or 15-Deoxy-Δ12,14-prostaglandin J2 (J2; 5 μM) pretreatment for 3 h (n=3). g NO 
production in cells treated as in f-j using a Greiss reagent kit (n=3). Data are mean ± s.e.m, of at least 3 replicates. 
*p<0.05, ***p<0.001, ****p<0.0001 one-way ANOVA. Blots are representative of 3 experiments.  
 a  b  
Extended Data Figure 9. An Nrf2-dependent feedback loop exists between itaconate and IFN-β. a  Isg20 and Irf5 
mRNA expression in BMDMs treated with poly I:C (40 μg/ml,) for 24 h ± OI pre-treatment (125 μM) for 3 h (n=6). b IL-10 
mRNA (n=3) and protein (n=5) expression in BMDMs treated with LPS (100 ng/ml) for 4 (left panel) or 24 (right panel) ± 
IFN-β treatment (1000 U/ml) for 3 h. c Isg20 expression in BMDMs transfected with two different Nrf2 (50 nM) siRNAs 
compared with non-silencing control following treatment with LPS for 6 h ± OI (125 μM) pretreatment for 3 h (n=6). d 
 ISG20 mRNA expression in WT (n=2) and Nrf2 KO (n=4) BMDMs treated with LPS for 6 h ± OI (125 μM) pretreatment 
for 3 h. e ISG20 mRNA expression in BMDMs treated with LPS for 24 h ± diethyl maleate (DEM; 100 μM) or 15-Deoxy-
Δ 12,14-prostaglandin J2 (J2; 5 μM) pretreatment for 3 h (n=3). Data are mean ± s.e.m, of at least 3 replicates. **p<0.01, 
***p<0.001, ****p<0.0001 one-way ANOVA.  
Table 1 – Cysteine/Lysine Residue(s) in Keap1 modified by OI as determ-ined by tandem mass spectrometry  
4-OI 
Residue 
Peptide  
Amino Acid  
Position 
Peptide Sequence -10logP Enzyme Digest 
Type 
Cys23 22-31 S.KC(+242.15)PEGAGDAV.M 31.47 Elastase In Gel 
Cys151 144-152 A.SISVGEKC(+242.15)V.L 44.11 Elastase In Gel 
 146-152 I.SVGEKC(+242.15)V.L 30.95 
144-153 A.SISVGEKC(+242.15)VL.H 30.25 145-152 S.ISVGEKC(+242.15)V.L 
29.32 
Cys257 254-260 V.KYDC(+242.15)PQR.R 35.44 Elastase In Gel 
 255-260 K.YDC(+242.15)PQR.R 40.13 Trypsin In Gel 
 255-260 K.YDC(+242.15)PQR.R 41.08 Trypsin In Solution 
Cys273 273-279 R.C(+242.15)HALTPR.F 35.93 Trypsin In Gel 
 273-279 R.C(+242.15)HALTPR.F 38.65 Trypsin In Solution 
Cys288 282-293 L.QTQLQKC(+242.15)EILQA.D 41.70 Elastase In Gel 
 282-290 L.QTQLQKC(+242.15)EI.L 36.70   
 284-293 T.QLQKC(+242.15)EILQA.D 33.47   
 280-296 R.FLQTQLQKC(+242.15)EILQADAR.C 55.81 Trypsin In Gel 
 288-296 K.C(+242.15)EILQADAR.C 50.84   
 288-296 K.C(+242.15)EILQADAR.C 48.80 Trypsin In Solution 
Cys297 294-304 A.DARC(+242.15)KDYLVQI.F 37.15 Elastase In Gel 
K615 602-615 R.SGVGVAVTMEPCRK(+242.15).Q 37.59 Trypsin In Gel 
 602-615 R.SGVGVAVTM(+15.99)EPCRK(+242.15).Q 36.40   
Extended Data Table 1. Cysteine/Lysine Residue(s) in Keap1 modified by OI as determined by tandem mass 
spectrometry 
 Table 2 - Cysteine residues modified by itaconate identified using tandem mass spectrometry  
LPS-treated 
BMDMs 
OI-treated 
BMDMs 
Extended 
Data 
Table 2. 
Cysteine 
residues modified following treatment with LPS (100 ng/ml) for 24 h (top) or OI (250 μM) (bottom) for 4 h. 
Protein  
Alkylated 
residue 
Peptide amino 
acid position 
Peptide sequence  
X score Ppm 
Plsl 
Cys111 
97-123 KEGIC(+4.98)AIGGTSEQSSVGTQHSYSEEEK 5.998 -2.22 
Acon Cys385 378-395 VGLIGSC(+4.98)TNSSYEDMGR 4.212 4.17 
Ldha 
Cys84 
82-90 
DYC(4.98)VTANSK 
3.474 -2.91 
Anxa1 
Cys189 186-204 
GDRC(4.98)QDLSVNQDLADTDAR 3.514 -0.48 
Ifi5b Cys317 
310-320 QMIEVPNC(+4.98)ITR 2.412 -4.16 
Ipyr2 Cys156, 157 153-171 STDC(4.98)C(+4.98)GDNDPIDVCEIGSK 4.664 22.60 
Ef2 Cys41  33-42 STLTDSLVC(+4.98)K  3.677 -1.41 
Thio Cys73 73-81 C(+4.98)MPTFQFYK 2.422 -2.22 
Protein  
Alkylated 
residue 
Peptide amino 
acid position 
Peptide sequence  
X score Ppm 
Gilt 
Cys69 
61-73 VSLYYESLC(+4.98)GACR 4.677 3.40 
Fgd6  Cys1004 9996-1005  NVALLDEQC(+4.98)K 3.759  -7.98  
Olfr644 
Cys306 
305-313 
FC(+4.98)KILLGNK 
3.155 -2.10 
Ldha 
Cys84 82-90 
DYC(+4.98)VTANSK 2.832 3.88 
Padi6 Cys553 
553-558 C(+4.98)ISLNR 2.446 -18.58 
Ubr4 Cys4241 4237-4244 LIASC(+4.98)HWK 2.421 -7.45 
Hmox2  Cys314  314-323  C(+4.98)PFYAAQPDK 2.279  2.89  
Lhpp Cys113 112-118 
  
FC(+4.98)TNESQK 2.169 -11.64 
